IAVI P001: A Phase I Double-Blind, Placebo-Controlled, Randomized Trial to Evaluate the Safety and Immunogenicity of TBC-M4, a multigenic MVA HIV Vaccine vs ADVAX, a multigenic DNA HIV Vaccine followed by TBC-M4, a multigenic MVA HIV Vaccine

Trial Profile

IAVI P001: A Phase I Double-Blind, Placebo-Controlled, Randomized Trial to Evaluate the Safety and Immunogenicity of TBC-M4, a multigenic MVA HIV Vaccine vs ADVAX, a multigenic DNA HIV Vaccine followed by TBC-M4, a multigenic MVA HIV Vaccine

Active, no longer recruiting
Phase of Trial: Phase I

Latest Information Update: 24 Aug 2016

At a glance

  • Drugs ADVAX (Primary) ; HIV vaccine-TBC M4 (Primary)
  • Indications HIV infections
  • Focus Adverse reactions
  • Most Recent Events

    • 10 Mar 2010 Status changed from recruiting to active, no longer recruiting as reported by Clinical Trials Registry - India
    • 27 Aug 2008 New trial record.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top